Evaluation of Risk Factors for Premature Discontinuation of Injection Treatment With Betaferon in Patients With Relapsing Forms of Multiple Sclerosis.
Phase of Trial: Phase IV
Latest Information Update: 24 Jun 2013
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms BREAK
- Sponsors Bayer
- 27 Apr 2012 Actual initiation date changed from Nov 2008 to Sep 2008 as reported by ClinicalTrials.gov.
- 27 Apr 2012 Actual patient number changed from 827 to 848 as reported by ClinicalTrials.gov.
- 27 Apr 2012 Actual end date (Dec 2011 ) added as reported by ClinicalTrials.gov.